8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (May 1, 2012)

Filed May 1, 2012For Securities:BIIB

Summary

Biogen Idec Inc. filed an 8-K on May 1, 2012, to report its financial results for the first quarter ended March 31, 2012. This filing primarily incorporates a press release detailing the company's operational and financial performance during the period. While the 8-K itself is a brief procedural document, the furnished press release (Exhibit 99) would contain the substantive financial and operational data that investors would examine to understand the company's performance, including revenue, earnings, product sales, and any forward-looking statements or strategic updates. Investors should review the press release attached as Exhibit 99 to this 8-K for specific details on Biogen Idec's Q1 2012 performance. Key areas of interest would include the sales of its key drugs, progress in its product pipeline, and any commentary provided by management on market conditions and future outlook. It's important to note that this press release is furnished and not deemed 'filed' under Section 18 of the Exchange Act.

Key Highlights

  • 1Biogen Idec announced its Q1 2012 financial results via an 8-K filing on May 1, 2012.
  • 2The filing incorporates a press release (Exhibit 99) containing detailed results of operations and financial condition.
  • 3Investors can find specific Q1 2012 financial and operational data within the furnished press release.
  • 4The press release provides information on the company's performance for the three months ended March 31, 2012.
  • 5This filing serves as a notification mechanism for timely disclosure of material financial information.
  • 6The press release is furnished and not considered 'filed' for regulatory purposes under Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Biogen Idec's financial results for the first quarter ended March 31, 2012. It incorporates by reference a press release that contains the detailed operational and financial information for that period.

The specific financial and operational details are located in the press release furnished as Exhibit 99 to this 8-K filing. Investors should refer to that document for comprehensive information.

No, the press release furnished as Exhibit 99 is considered 'furnished' and not 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same liability implications as a formally filed document under that section.

Typically, a press release accompanying an 8-K for financial results includes details on revenue, net income, earnings per share (EPS), sales performance of key products, updates on the drug pipeline, and management's commentary on the company's performance and outlook.